HEPATOLOGY 润色咨询

HEPATOLOGY

出版年份:1981 年文章数:5641 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:4.5% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2020-05-14 xrkguoguo

    想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。

    2

    展开2条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-29 小动量

    方法的撰写顺序/逻辑顺序是什么?

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2019-10-10 qmac

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志

    2

    展开2条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2019-02-05 半夜吹口哨

    请问作者签名确认必须完成才会送审吗?凱凱 2018-02-03 23:24:00 发表:
    2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
    總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

    凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject.
    總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-27 rayms

    结果中的重要文献是在结果体现,还是在引言中描述?

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2019-05-03 Cure

    审稿速度:1.0 | 投稿命中率:5.0
    经验分享:投了一篇clinical trial
    04/04/2019 Submission
    04/05/2019 Selecting/Assigning Reviewers
    04/08/2019 Under Review
    04/09/2019 Selecting/Assigning Reviewers
    04/09/2019 Under Review
    04/22/2019 Reviews Returned
    05/01/2019 Evaluating Reviews
    05/02/2019 Reject with Transfer – HepComm
    非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2019-10-25 147612bem32暂无昵称

    再等等看吧

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2024-03-26 Charls.Guo 来自上海

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:肝硬化;预测模型
    经验分享:肝病4大顶刊之一,有幸中了一篇。
    贡献一个timeline;
    07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit
    5-Mar-2024 修回 - 24-Mar-2024 accept

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2022-12-10 ms6000001750417887 来自北京

    一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=590830, encodeId=7b49590830a8, content=想向大家请教下 hepatology要求字数不能超过6000字包括引用 不知道是否包括legend。 还有引用文献的数量是否包括补充材料里面的引用。all submission must adhere to the 50 reference limit.不确定是各自符合50的限制还是加起来符合50的限制。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e451607689, createdName=xrkguoguo, createdTime=Thu May 14 00:00:00 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091080, encodeId=bd131091080bd, content=方法的撰写顺序/逻辑顺序是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577644, encodeId=56125e76441a, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:今年有幸中了一篇,顺利毕业,很开心,总的来说,审稿速度非常快,投稿后两周返修,大修,修改了三个月后投回,一周后返修,三个审稿人只有一个审稿人有问题,没有补实验,只是进行了解释并投回,一周后接受,还是比较顺利的,三个审稿人的意见主要侧重于临床表型的方面,对机制要求并不高,但故事要完整,很好的老牌医学杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoH8V3JLyBxbA8vW2nAyLAn8vQtee0bQqyFL0lpGqmFI4QvicleHC1ZLWp4ASyWPqfrEHGtbMmficeQ/132, createdBy=fa152442300, createdName=qmac, createdTime=Thu Oct 10 17:09:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=566480, encodeId=fa5156648090, content=请问作者签名确认必须完成才会送审吗?<span class="quote">凱凱 2018-02-03 23:24:00 发表:<br>2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果.</span>, beContent=凱凱 2018-02-03 23:24:00 发表: 2017年11月底submit, 兩周後進入review, 過了兩周又重新選擇reviewer ,估計是其中一位過聖誕節去了. 又拖了兩周review才回到editor手上. 再等兩周Reject. <br> 總共等了兩個多月. 著重在沒有實際手作的病理分析,目前為付費網站的病理分析結果., objectType=tool_impact_factor, channel=null, level=null, likeNumber=225, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c741659779, createdName=半夜吹口哨, createdTime=Tue Feb 05 00:00:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1091079, encodeId=24f110910e998, content=结果中的重要文献是在结果体现,还是在引言中描述?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570377, encodeId=76f45e03771d, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:投了一篇clinical trial <br> 04/04/2019 Submission <br> 04/05/2019 Selecting/Assigning Reviewers <br> 04/08/2019 Under Review <br> 04/09/2019 Selecting/Assigning Reviewers <br> 04/09/2019 Under Review <br> 04/22/2019 Reviews Returned <br> 05/01/2019 Evaluating Reviews <br> 05/02/2019 Reject with Transfer – HepComm <br> 非常诡异的是,经历了一个月选审稿人又重选审稿人又under review的状态,最后的拒信居然没有外审意见,说内部编辑觉得不合适直接拒的。已写信询问。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=244, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=af765089489, createdName=Cure, createdTime=Fri May 03 04:49:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578795, encodeId=ead55e87956f, content=再等等看吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=213, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2195450, encodeId=e18321954505a, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:肝硬化;预测模型<br>经验分享:肝病4大顶刊之一,有幸中了一篇。<br>贡献一个timeline;<br>07-Dec-2023~28 - Dec-2023 reject with opportunity to resubmit<br>5-Mar-2024 修回 - 24-Mar-2024 accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5bbd5545529, createdName=Charls.Guo, createdTime=Tue Mar 26 15:41:46 CST 2024, time=2024-03-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2105210, encodeId=fc9c21052106c, content=一审给了拒稿修改后重投,现在修回去了,但是刚提交几个小时状态就变成了reviews returned, 有大佬知道这是为啥吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5dc6457055, createdName=ms6000001750417887, createdTime=Sat Dec 10 11:31:58 CST 2022, time=2022-12-10, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1076077, encodeId=195c10e607712, content=审稿速度:1.0 | 投稿命中率:5.0<br>经验分享:回顾性临床研究<br>11.18投稿,12.2拒稿<br>附两个审稿人的审稿意见<br>编辑建议转投hc, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Thu Dec 02 07:24:00 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-02 YJJJJJ

    审稿速度:1.0 | 投稿命中率:5.0
    经验分享:回顾性临床研究
    11.18投稿,12.2拒稿
    附两个审稿人的审稿意见
    编辑建议转投hc

    0

共151条页码: 2/16页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分